The Manaus Declaration: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group

The International Histoplasmosis Advocacy Group (iHAG)

doi:10.1007/s12281-019-00365-3

The Manaus Declaration: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group

Título traducido de la contribución: Situación actual de la histoplasmosis en las Américas, Informe de la II Reunión Regional del Grupo Internacional de Defensa de la Histoplasmosis

The International Histoplasmosis Advocacy Group (iHAG)

Grupo de Estudios en Microbiología Traslacional y Enfermedades Emergentes - MICROS

Producción científica: Contribución a revista › Artículo de revisión › revisión exhaustiva

27 Citas (Scopus)

Resumen

Objetivo de la revisión: El objetivo de este informe es resumir las conclusiones de la II Reunión Regional sobre Histoplasmosis en las Américas celebrada en Manaus, Brasil, del 22 al 24 de marzo de 2019. Hallazgos recientes: Las personas que viven con VIH avanzado tienen un alto riesgo de desarrollar histoplasmosis. Los signos y síntomas clínicos de esta enfermedad suelen ser inespecíficos, lo que dificulta establecer un diagnóstico. Sin embargo, con los recientes avances tecnológicos, los diagnósticos in vitro y los medicamentos para la histoplasmosis a menudo no están disponibles en muchas regiones del mundo. Además, la histoplasmosis a menudo no se incluye en los programas de atención y tratamiento del VIH, lo que da como resultado una planificación inadecuada del sistema de salud y oportunidades perdidas para salvar vidas. Resumen: La II Reunión Regional sobre Histoplasmosis en las Américas reunió a una audiencia multidisciplinaria. Las recomendaciones desarrolladas para ser incluidas en las directrices de la OMS para el diagnóstico y tratamiento de la histoplasmosis en el VIH avanzado fueron el producto de esta reunión, y las directrices se publicarán a principios de 2020.

Título traducido de la contribución	Situación actual de la histoplasmosis en las Américas, Informe de la II Reunión Regional del Grupo Internacional de Defensa de la Histoplasmosis
Idioma original	Inglés estadounidense
Páginas (desde-hasta)	244-249
Número de páginas	6
Publicación	Current Fungal Infection Reports
Volumen	13
N.º	4
DOI	https://doi.org/10.1007/s12281-019-00365-3
Estado	Publicada - dic. 1 2019

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Áreas temáticas de ASJC Scopus

Enfermedades infecciosas

Acceder al documento

10.1007/s12281-019-00365-3

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'Situación actual de la histoplasmosis en las Américas, Informe de la II Reunión Regional del Grupo Internacional de Defensa de la Histoplasmosis: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group'. En conjunto forman una huella única.

Citar esto

@article{56338ffff2384cdcb669daad2e4ecc79,

title = "The Manaus Declaration: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group",

abstract = "Purpose of Review: The aim of this report is to summarize the conclusions of the II Regional Meeting on Histoplasmosis in the Americas held in Manaus, Brazil, on March 22–24, 2019. Recent Findings: Persons living with advanced HIV are at high risk for developing histoplasmosis. Clinical signs and symptoms of this disease are often non-specific, making it difficult to establish a diagnosis. Although with the recent technological advances, in vitro diagnostics and medicines for histoplasmosis are often not available in many regions around the world. In addition, histoplasmosis is often not included in HIV care and treatment programs, resulting in inadequate health system planning and missed opportunities to save lives. Summary: The II Regional Meeting on Histoplasmosis in the Americas gathered a multidisciplinary audience. Developed recommendations to be included in the WHO guidelines for diagnosis and treatment of histoplasmosis in advanced HIV were the product of this meeting, and guidelines are aimed to be published in early 2020.",

author = "\{The International Histoplasmosis Advocacy Group (iHAG)\} and Caceres, \{Diego H.\} and Antoine Adenis and \{de Souza\}, \{Jo{\~a}o Vicente Braga\} and Gomez, \{Beatriz L.\} and Cruz, \{Katia Santana\} and Pasqualotto, \{Alessandro C.\} and Giovanni Ravasi and Freddy Perez and Tom Chiller and \{de Lacerda\}, \{Marcus Vinicius Guimarares\} and Mathieu Nacher",

note = "Funding Information: The second meeting of the international Histoplasmosis Advocacy Group (iHAG 2019) was co-organized by the International Histoplasmosis Advocacy Group (iHAG), Instituto Nacional de Pesquisas da Amaz{\^o}na (INPA-Brazil), Funda{\c c}{\~a}o de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD-Brazil), Pan American Health Organization (PAHO)/World Health Organization (WHO), and the Centers for Disease Control and Prevention (CDC). The meeting was supported by the Funda{\c c}{\~a}o de Amparo a Pesquisa do Estado do Amazonas (FAPEAM) (Grant No 005/2017 Program to Support the Holding of Scientific and Technological Events in the State of Amazonas—PAREV), Funda{\c c}{\~a}o Oswaldo Cruz (Fiocruz), Global Action Fund for Fungal Infections (GAFFI), International Society for Human and Animal Mycology (ISHAM), Mycoses Study Group Education and Research Consortium (MSGERC), Centre d'Investigation Clinique Antilles Guyane (Inserm CIC1424) of the Centre Hospitalier de Cayenne, Universidad del Rosario, Universidade Federal de Ci{\^e}ncias da Sa{\'u}de de Porto Alegre (UFCSPA), and Santa Casa de Miseric{\'o}rdia de Porto Alegre. Publisher Copyright: {\textcopyright} 2019, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",

year = "2019",

month = dec,

day = "1",

doi = "10.1007/s12281-019-00365-3",

language = "English (US)",

volume = "13",

pages = "244--249",

journal = "Current Fungal Infection Reports",

issn = "1936-3761",

publisher = "Springer",

number = "4",

}

The Manaus Declaration: Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group. / The International Histoplasmosis Advocacy Group (iHAG).
En: Current Fungal Infection Reports, Vol. 13, N.º 4, 01.12.2019, p. 244-249.

Producción científica: Contribución a revista › Artículo de revisión › revisión exhaustiva

TY - JOUR

T1 - The Manaus Declaration

T2 - Current Situation of Histoplasmosis in the Americas, Report of the II Regional Meeting of the International Histoplasmosis Advocacy Group

AU - The International Histoplasmosis Advocacy Group (iHAG)

AU - Caceres, Diego H.

AU - Adenis, Antoine

AU - de Souza, João Vicente Braga

AU - Gomez, Beatriz L.

AU - Cruz, Katia Santana

AU - Pasqualotto, Alessandro C.

AU - Ravasi, Giovanni

AU - Perez, Freddy

AU - Chiller, Tom

AU - de Lacerda, Marcus Vinicius Guimarares

AU - Nacher, Mathieu

N1 - Funding Information: The second meeting of the international Histoplasmosis Advocacy Group (iHAG 2019) was co-organized by the International Histoplasmosis Advocacy Group (iHAG), Instituto Nacional de Pesquisas da Amazôna (INPA-Brazil), Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD-Brazil), Pan American Health Organization (PAHO)/World Health Organization (WHO), and the Centers for Disease Control and Prevention (CDC). The meeting was supported by the Fundação de Amparo a Pesquisa do Estado do Amazonas (FAPEAM) (Grant No 005/2017 Program to Support the Holding of Scientific and Technological Events in the State of Amazonas—PAREV), Fundação Oswaldo Cruz (Fiocruz), Global Action Fund for Fungal Infections (GAFFI), International Society for Human and Animal Mycology (ISHAM), Mycoses Study Group Education and Research Consortium (MSGERC), Centre d'Investigation Clinique Antilles Guyane (Inserm CIC1424) of the Centre Hospitalier de Cayenne, Universidad del Rosario, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), and Santa Casa de Misericórdia de Porto Alegre. Publisher Copyright: © 2019, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Purpose of Review: The aim of this report is to summarize the conclusions of the II Regional Meeting on Histoplasmosis in the Americas held in Manaus, Brazil, on March 22–24, 2019. Recent Findings: Persons living with advanced HIV are at high risk for developing histoplasmosis. Clinical signs and symptoms of this disease are often non-specific, making it difficult to establish a diagnosis. Although with the recent technological advances, in vitro diagnostics and medicines for histoplasmosis are often not available in many regions around the world. In addition, histoplasmosis is often not included in HIV care and treatment programs, resulting in inadequate health system planning and missed opportunities to save lives. Summary: The II Regional Meeting on Histoplasmosis in the Americas gathered a multidisciplinary audience. Developed recommendations to be included in the WHO guidelines for diagnosis and treatment of histoplasmosis in advanced HIV were the product of this meeting, and guidelines are aimed to be published in early 2020.

AB - Purpose of Review: The aim of this report is to summarize the conclusions of the II Regional Meeting on Histoplasmosis in the Americas held in Manaus, Brazil, on March 22–24, 2019. Recent Findings: Persons living with advanced HIV are at high risk for developing histoplasmosis. Clinical signs and symptoms of this disease are often non-specific, making it difficult to establish a diagnosis. Although with the recent technological advances, in vitro diagnostics and medicines for histoplasmosis are often not available in many regions around the world. In addition, histoplasmosis is often not included in HIV care and treatment programs, resulting in inadequate health system planning and missed opportunities to save lives. Summary: The II Regional Meeting on Histoplasmosis in the Americas gathered a multidisciplinary audience. Developed recommendations to be included in the WHO guidelines for diagnosis and treatment of histoplasmosis in advanced HIV were the product of this meeting, and guidelines are aimed to be published in early 2020.

UR - https://www.scopus.com/pages/publications/85075916707

UR - https://www.scopus.com/pages/publications/85075916707#tab=citedBy

U2 - 10.1007/s12281-019-00365-3

DO - 10.1007/s12281-019-00365-3

M3 - Review article

AN - SCOPUS:85075916707

SN - 1936-3761

VL - 13

SP - 244

EP - 249

JO - Current Fungal Infection Reports

JF - Current Fungal Infection Reports

IS - 4

ER -